Notifications can be managed in browser preferences.
One early adopter describes how he was in remission ‘within the first two or three weeks’ after the treatment
I would like to be emailed about offers, events and updates from The Independent. Read our Privacy notice
Blood cancer patients in England are set to be among the first in the world to access a pioneering "Trojan horse" treatment, health officials have announced.
The targeted therapy, belantamab mafodotin, also known as Blenrep, has shown promising results in halting the progression of myeloma for nearly three times as long as current treatments, according to studies.
